Loading
CW
Charlotte's Web Holdings, Inc. Stock: price and insider trades · United States
1 insider bought €34k of shares over the last 90 days, the latest by Kunkel Raymond J., filed 04 Sept 2026.
Charlotte's Web Holdings, Inc.: what insiders have been doing
Charlotte's Web Holdings, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 24 October 2025 and 24 October 2026, 18 insiders published 62 filings.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €58k, made by 3 insiders. The totals do not cover 1 filing with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 3 senior executives. At €34k, the purchase published on 4 September 2026 by Kunkel Raymond J. is the largest of the period (0.048% of market cap).
With 62 filings in twelve months, the company is more active than the median of 8 filings across the 281 companies we follow on the same exchange. Looking back to 2022, when coverage begins, insiders filed 12 purchases and 4 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 49.9 m USD and net income at -29.7 m USD.
The clock since the last published purchase (8 September 2026) now reads 46 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
187
Thresholds
n/a
Buy Volume
€119,854
12 ops. · all time
Sell Volume
€84,624
4 ops. · all time
Who traded when
BuySaleRaymond J. Kunkel5 buys
William Morachnick1 buy1 sale
Raymond Kunkel1 buy
Rogers, Stephen1 sale
Stanley, Jared1 sale
Since the insiders bought
- -20.0%Entry US$0.33 · Close at T+30 US$0.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,983 of 26,289 companies
15.6
score / 100
Value8
Quality24
FCF yld-22%
Earn yld-45%
EV/EBITDA·
ROE-97%
Gross mgn43%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.24
Analyst consensus
1.00/5
Income statement
RevenueUS$49.9M
Gross profitUS$21.7M43% margin
EBITDA-US$13.9M-28% margin
Net income-US$29.7M-73.6% margin
Valuation
P/Book1.2x
Beta2.25
Balance sheet & cash
Market capUS$66.3M
Total debtUS$64.5M
Free Cash Flow-US$14.7M
Debt / Equity23%
Profitability & ownership
ROE-97.1%
ROA-14.9%
% insiders47.3%
% institutions1.4%
Last declaration on 2 October 2026
Declarations187 total
222,911 sharesCommon SharesTSXSEDI:4785864
294,662 shares@ CA$0.280339.0% of flowRights Restricted Share AwardsTSXSEDI:4785861
283,687 sharesCommon SharesTSXSEDI:4785855
375,000 shares@ CA$0.270547.8% of flowRights Restricted Share AwardsTSXSEDI:4785850
375,000 shares0Common SharesSEC:0001750155-26-000123:0
294,662 shares0Common SharesSEC:0001750155-26-000125:0
91,313 shares@ US$0.27050.033% mcap8.2% of flowCommon SharesSEC:0001750155-26-000123:1
71,751 shares@ US$0.28030.027% mcap6.3% of flowCommon SharesSEC:0001750155-26-000125:1
137,935 shares@ CA$0.28480.038% mcap100.0% of flowCommon SharesTSXSEDI:4773849
Canonical exit: 2 Dec 2026 (T+90)
137,935 shares@ US$0.2850.048% mcap34.1% of flowCommon SharesSEC:0001750155-26-000121:0
Canonical exit: 2 Dec 2026 (T+90)
85,000 sharesRights Restricted Share AwardsTSXSEDI:4747816
85,000 sharesCommon SharesTSXSEDI:4747814
75,000 sharesRights Restricted Share AwardsTSXSEDI:4747783
75,000 sharesCommon SharesTSXSEDI:4747781
75,000 sharesRights Restricted Share AwardsTSXSEDI:4747292
75,000 sharesCommon SharesTSXSEDI:4747288
294,661 sharesRights Restricted Share AwardsTSXSEDI:4747212
222,911 sharesCommon SharesTSXSEDI:4747206
75,000 shares0Common SharesSEC:0001750155-26-000104:0
75,000 shares0Common SharesSEC:0001750155-26-000106:0
85,000 shares0Common SharesSEC:0001750155-26-000105:0
294,661 shares0Common SharesSEC:0001750155-26-000107:0
71,750 shares@ US$0.310.028% mcap8.0% of flowCommon SharesSEC:0001750155-26-000107:1
91,313 shares@ CA$0.310.025% mcap100.0% of flowCommon SharesTSXSEDI:4743891
375,000 sharesRights Restricted Share AwardsTSXSEDI:4743890
25 of 187 declarations
About Charlotte's Web Holdings, Inc.
Charlotte’s Web Holdings, Inc. is a United States-based company focused on hemp extract and botanical wellness products. It is an SEC-reporting issuer with insider activity disclosed through Form 4 filings, and its shares are primarily followed in the U.S. small-cap / OTC ecosystem, while market references may also appear in the context of NYSE/NASDAQ screening and data feeds. For international investors, the company should be viewed as a consumer health and wellness name rather than a traditional pharmaceutical developer. Charlotte’s Web is headquartered in Louisville, Colorado, United States, and the business conducts the majority of its operations in the U.S. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai))
The company was built around its Charlotte’s Web brand and proprietary hemp genetics, evolving into a portfolio-led platform in cannabidiol (CBD) and related botanical ingredients. Its brand family currently includes Charlotte’s Web™, CBD Medic™, and CBD Clinic™, with positioning centered on wellness, self-care, and functional use cases. Core product categories include liquid hemp extract tinctures, gummies, capsules, topical creams and lotions, pet products, and, more recently, functional mushroom gummies. This broad but still focused range allows the company to address multiple consumer needs such as sleep, calm, daily wellness, recovery, and topical relief. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai))
Read moreShow less
Operationally, Charlotte’s Web relies on an integrated model spanning North American farm-grown hemp inputs, extraction, manufacturing, quality control, R&D, and distribution. A key asset is its cGMP-compliant production facility in Louisville, where the company manufactures tinctures and manages distribution and quality systems. Its products are sold through selected distributors, healthcare practitioners, the company’s own website, and third-party e-commerce channels. This vertical integration is important in a category where product consistency, trust, and compliance can be decisive competitive factors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai))
From a competitive standpoint, Charlotte’s Web describes itself as a market leader in hemp extract wellness products in the United States. Its competitive strengths are brand recognition, proprietary hemp genetics, a diversified SKU set, and a long operating history in a still-developing consumer health niche. At the same time, the business remains exposed to pricing pressure, consumer demand swings, and regulatory uncertainty around hemp-derived products. For equity investors, the investment case is therefore a balance between brand equity and execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai))
A major recent development came on March 30–31, 2026, when the company announced a transaction with BAT involving the conversion of a C$75.3 million convertible debenture into common shares and a concurrent $10 million equity investment. That transaction is strategically important because it may materially reshape the company’s ownership structure and capital base. The company also reported its 2025 annual results in late March 2026, continuing to emphasize its leadership in CBD hemp extract wellness products. For French, Belgian, and Swiss investors, Charlotte’s Web is best characterized as a speculative U.S. consumer health small cap with meaningful dilution, funding, and execution considerations, but with a recognized brand and a clear niche in the U.S. wellness market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001750155/000175015526000029/cweb-20251231.htm?utm_source=openai))
